Question 1

What are GLP‑1 medications?

Accepted Answer

GLP‑1 receptor agonists (like semaglutide and tirzepatide) are prescription medicines that help regulate appetite and blood sugar. They are used for weight management and type 2 diabetes under clinical supervision.

Question 2

How do I know if I'm eligible?

Accepted Answer

Eligibility varies by provider, but many follow criteria such as BMI ≥ 30, or ≥ 27 with relevant comorbidities. Our BMI checker offers an educational starting point—final decisions rest with clinicians.

Question 3

What side effects should I expect?

Accepted Answer

Common effects include nausea, fullness, and GI symptoms, especially during dose increases. Always review risks, warnings, and patient information with your clinician.

Question 4

Do you list prices and providers?

Accepted Answer

We highlight how to compare provider policies (delivery, consultation fees, stock updates) and share methods for safe, apples‑to‑apples comparisons. Always verify the latest price and terms on the provider's site.

Question 5

Is glp.space affiliated with any pharmacy?

Accepted Answer

No. We do not accept sponsorships or affiliate fees. Our aim is independent, patient‑first transparency.

Question 6

What is Mounjaro?

Accepted Answer

Mounjaro (tirzepatide) is a once-weekly injectable medication for weight management. It targets both GIP and GLP-1 receptors to reduce appetite and improve blood sugar control. Clinical trials show 20–22.5% average weight loss over 68–72 weeks.

Question 7

How does Mounjaro work?

Accepted Answer

Dual-action technology:

• Activates GLP-1 receptors for fullness signals
• Activates GIP receptors for energy balance
• Reduces appetite with smaller portions
• Maintains steady blood sugar levels

Question 8

Who can use Mounjaro?

Accepted Answer

Adults with:

• BMI ≥30 (obesity)
• BMI 27–29.9 with weight-related conditions
• Age 18+
• Not pregnant
• No thyroid cancer history (MTC/MEN-2)
• No pancreatitis history

Question 9

How is Mounjaro administered?

Accepted Answer

Once-weekly subcutaneous injection using a pre-filled pen. Self-administered after training. Inject in abdomen, thigh, or upper arm; rotate sites weekly.

Question 10

What are the side effects of Mounjaro?

Accepted Answer

Common: nausea, diarrhoea/constipation, reduced appetite, vomiting, abdominal discomfort. Usually mild and improve over time. Rare serious effects: pancreatitis, gallbladder problems, allergic reactions, kidney problems.

Question 11

Is Mounjaro safe during pregnancy?

Accepted Answer

No. Not recommended for pregnant individuals or those planning pregnancy. Contact your healthcare provider immediately if you become pregnant while taking Mounjaro.

Question 12

How long does it take to see results with Mounjaro?

Accepted Answer

Reduced appetite within days. Weight loss begins in 2–4 weeks. Significant weight loss (≥5%) in 12–16 weeks, with continued improvement over 68–72 weeks.

Question 13

What is the minimum age for Mounjaro?

Accepted Answer

Approved for adults 18+. No upper age limit. Your healthcare provider will assess your health and medical history to determine appropriateness.

Question 14

What do clinical trials show about Mounjaro?

Accepted Answer

Impressive results:

• 20–22.5% average weight loss over 68–72 weeks
• 91% lost ≥5% body weight
• 50% lost ≥20% body weight
• Improved cardiovascular risk factors
• Enhanced quality of life

Question 15

How much does Mounjaro cost in the UK?

Accepted Answer

Costs vary by provider and dose. Private prescriptions typically £200–400 per month. Transparent pricing with no hidden fees. Compare prices from verified, GPhC-registered pharmacies.

Question 16

What is Wegovy?

Accepted Answer

Wegovy (semaglutide) is a once-weekly injectable GLP-1 medication for medical weight management. It reduces appetite, enhances fullness, and supports sustainable weight loss alongside lifestyle changes. Clinical trials show around 10–15% average weight loss over 68 weeks.

Question 17

How does Wegovy work?

Accepted Answer

GLP-1 action:

• Enhances satiety signals in the brain
• Slows gastric emptying (you feel full longer)
• Reduces appetite and cravings
• Improves insulin response and stabilises blood sugar

Question 18

Who can use Wegovy?

Accepted Answer

Adults with:

• BMI ≥30 (obesity)
• BMI 27–29.9 with a weight-related condition (e.g., hypertension, dyslipidaemia, sleep apnoea)
• Age 18+
• Not pregnant or breastfeeding
• No personal/family history of medullary thyroid carcinoma (MTC) or MEN-2
• No pancreatitis history (discuss risks with your clinician)

Question 19

How is Wegovy administered?

Accepted Answer

Once-weekly subcutaneous injection using a pre-filled pen. Self-administered after training. Inject in abdomen, thigh, or upper arm; rotate injection sites weekly.

Question 20

What are the side effects of Wegovy?

Accepted Answer

Common: nausea, diarrhoea/constipation, reduced appetite, vomiting, abdominal discomfort, headache. Usually mild and improve over time. Rare serious effects: pancreatitis, gallbladder problems, allergic reactions, kidney problems. Seek care for severe abdominal pain.

Question 21

Is Wegovy safe during pregnancy?

Accepted Answer

No. Not recommended during pregnancy or breastfeeding. If planning pregnancy, discuss stopping Wegovy in advance. Contact your healthcare provider immediately if you become pregnant while taking Wegovy.

Question 22

How long does it take to see results with Wegovy?

Accepted Answer

Reduced appetite within days. Weight loss typically begins in 2–4 weeks. Many people reach ≥5% loss by 12–16 weeks, with continued improvement over 6–12 months when combined with lifestyle support.

Question 23

What is the minimum age for Wegovy?

Accepted Answer

Approved for adults 18+. Your healthcare provider will assess medical history and current medications to determine suitability.

Question 24

What do clinical trials show about Wegovy?

Accepted Answer

Results (STEP programme):

• ~10–15% average weight loss at 68 weeks
• High rates achieving ≥5% and ≥10% loss
• Improvements in blood pressure, glucose, and lipids
• Enhanced quality of life measures

Question 25

How much does Wegovy cost in the UK?

Accepted Answer

Costs vary by provider and dose. Private prescriptions typically £150–300 per month. Transparent pricing with no hidden fees. Compare prices from verified, GPhC-registered pharmacies.

Question 26

What does switching from Wegovy to Mounjaro mean?

Accepted Answer

Switching means transitioning from semaglutide (a GLP-1 receptor agonist) to tirzepatide (a dual GIP/GLP-1 therapy). The goal is often to enhance weight-loss results, improve glycaemic control, or address tolerability/plateau issues. Always switch under clinician supervision.

Question 27

How long should I wait between the two medications?

Accepted Answer

Typical washout guidance:

• If Wegovy dose is below 1 mg → pause about 2 weeks
• If Wegovy dose is 1 mg or higher → pause about 4 weeks

This helps prevent overlapping exposure and reduces nausea while your GLP-1 receptors reset.

Question 28

How do I estimate my Mounjaro start date?

Accepted Answer

Add the recommended washout to your last Wegovy injection date:

• <1 mg: last injection date + ~2 weeks
• ≥1 mg: last injection date + ~4 weeks

Confirm exact timing with your prescriber.

Question 29

What starting dose of Mounjaro should I use?

Accepted Answer

Label-based initiation: 2.5 mg once weekly for weeks 0–4, then increase gradually every 4 weeks as tolerated (5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg max). Start low and go slow to improve comfort and adherence.

Question 30

Why do people switch from Wegovy to Mounjaro?

Accepted Answer

Common reasons:

• Greater average weight loss in head-to-head data (SURMOUNT-5)
• Dual mechanism (adds GIP) supporting insulin and metabolic regulation
• Plateau or tolerability challenges on higher semaglutide doses
• Evolving goals for non-diabetic adults seeking further progress

Question 31

Is Mounjaro more effective than Wegovy?

Accepted Answer

In SURMOUNT-5, tirzepatide showed ~20.2% average weight loss vs ~13.7% with semaglutide (≈47% greater relative reduction). Real-world analyses (e.g., JAMA 2024/2025) also observed greater mean reductions with tirzepatide. Individual results vary.

Question 32

What side effects should I expect when switching?

Accepted Answer

Common GI effects (usually mild, improve in 4–6 weeks): nausea, bloating, constipation/diarrhoea; fatigue or dizziness; occasional injection-site reactions. Tips: smaller low-fat meals, slow eating, hydration, rotate injection sites, avoid large meals before injections.

Question 33

Does tirzepatide affect oral contraceptives?

Accepted Answer

Yes. Because tirzepatide can slow gastric emptying, it may reduce oral contraceptive absorption. Consider a non-oral or barrier method for 4 weeks after starting and 4 weeks after each dose increase. Discuss options with your clinician.

Question 34

What about cardiovascular outcomes?

Accepted Answer

Wegovy has proven MACE reduction (SELECT, NEJM 2023). Tirzepatide's outcome trials (e.g., SURPASS-CVOT, SUMMIT, FLOW) are ongoing. Early data suggest favourable effects on lipids, CRP, and blood pressure; definitive CV outcomes are expected as trials complete.

Question 35

Do I need to taper Wegovy before switching?

Accepted Answer

A taper may help minimise rebound appetite and GI discomfort. A typical approach spaces the last few injections to every 10–14 days, then begins a 2–4 week washout before starting tirzepatide. Your prescriber will tailor the plan.

Question 36

What is glp.space?

Accepted Answer

glp.space is the UK's independent comparison and education platform for GLP-1 weight loss medications. We provide evidence-based information, transparent provider comparisons, and educational guides to help you make informed healthcare decisions with your doctor.

Question 37

What is glp.space's mission?

Accepted Answer

Our mission is to provide independent, evidence-based GLP-1 education and provider comparisons. We're built on evidence and committed to clarity—helping people understand their options, costs, and provider policies in clear language with sources.

Question 38

Does glp.space sell medications or provide prescriptions?

Accepted Answer

No. We don't sell medicines and we're not a clinic or pharmacy. Our purpose is education so you can decide with your doctor, confidently. We don't prescribe, sell, or dispense medication—and we don't replace medical advice from a qualified professional.

Question 39

Is glp.space affiliated with any pharmacy or provider?

Accepted Answer

No. We do not accept sponsorships or affiliate fees. We have complete independence with no provider affiliations. Our aim is independent, patient-first transparency with no paid rankings and no ads—just transparent comparisons.

Question 40

How does glp.space verify provider information?

Accepted Answer

Every entry is cross-checked against official registers (GPhC) and provider pages. All listings are compiled from public UK sources: the GPhC register, official provider websites, and where applicable CQC listings or MHRA announcements. Each record is manually reviewed before inclusion and re-verified periodically. When information is missing, we say so clearly rather than guess.

Question 41

What content does glp.space provide?

Accepted Answer

We provide:

• Comprehensive guides on Wegovy, Mounjaro, and switching between medications
• Provider and price comparisons with up-to-date pricing, stock status, and key policies
• Clinical evidence summaries based on published trials and regulatory guidance
• Educational tools like BMI calculators
• Evidence-based articles and resources

Question 42

What are glp.space's core principles?

Accepted Answer

Our principles:

• Transparency: No hidden affiliate links, no pay-to-rank. If partnerships exist, we label them clearly.
• Verification: We corroborate every data point with official sources. "Unknown" beats guessing.
• Privacy-minimal: We collect only what's necessary for core functionality. No data sales.
• Safety first: GLP-1s are prescription-only medicines. Everything here is educational and not a substitute for medical advice.

Question 43

How often is glp.space updated?

Accepted Answer

We review listings regularly and re-check provider policies and pricing to reflect the latest public information, so comparisons stay accurate over time. Price tables reflect the latest public data available and may change without notice.

Question 44

Is glp.space free to use?

Accepted Answer

Yes. glp.space is free to access for all users. We provide free access with a transparent methodology. There are no hidden fees, subscriptions, or charges for using our comparison tools or educational content.

Question 45

Can glp.space provide medical advice?

Accepted Answer

No. glp.space is an educational platform only. We provide information to help you understand your options, but we cannot and do not provide medical advice. Always consult with a qualified healthcare professional for personal medical advice, prescriptions, and treatment decisions.

Provider	Cheapest
Verified PILLSORTED	£90.50(2.5 mg)
Verified LOCAL PHARMACY ONLINE	£119.00(2.5 mg)
Verified PHARMACY PLANET	£128.00(2.5 mg)

Compare Wegovy and Mounjaro Prices from UK Providers

Discount Mounjaro

Understanding GLP-1 Medications

Mounjaro (tirzepatide)

Wegovy (semaglutide)

Latest Guides

Mounjaro

Wegovy

Switching from Wegovy to Mounjaro

Switching from Mounjaro to Wegovy

Typical eligibility criteria

BMI Eligibility for GLP-1 Treatment

Prescription & Clinical Assessment

Clinical Responsibility & Provider Variation

No Ads, No Bias.

Frequently
asked
questions.

Filter by category:

Ready to compare providers and costs?